Incretin hormones and the satiation signal.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23295502.
- Also identified by DOI 10.1038/ijo.2012.208 and PMC identifier 3768099.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.
Medical subject headings
- Gastric Inhibitory Polypeptide
- Glucagon-Like Peptide 1
- Hyperglycemia
- Hypoglycemic Agents
- Incretins
- Obesity
- Peptides
- Receptors, Glucagon
- Venoms
- Weight Loss